Pediatric Multiple Endocrine Neoplasia (MEN)

One or more of your child’s endocrine glands may be affected. The glands most commonly involved include the:

• Pancreas
• Parathyroid
• Pituitary

Type 2 MEN

One or more of the endocrine glands may also be affected, but those most commonly involved including:

• Thyroid gland (almost 100% of the time)
• Adrenal gland (about 50% of the time)
• Parathyroid gland  (20% of the time)

Type 2 MEN is rare, affecting about 1 in 35,000 individuals. With either type, early diagnosis is critical to your child’s health. This hereditary cancer syndrome comes with a high risk of tumors and it may occur at ages younger than expected.

Two subtypes of Type 2

MEN2A

MEN2A is associated with increased risk for medullary cancer of the thyroid (MTC), pheochromocytoma and primary hyperparathyroidism (PHPT).

MEN2B

MEN2B is associated with increased risk for MTC, pheochromocytoma, mucosal neuromas (benign growths) of the lips and tongue, and distinctive physical characteristics, such as enlarged lips and tall and slender body type. Disease onset generally occurs during infancy or early childhood.

Familial medullary thyroid cancer (FMTC)

Familial medullary thyroid cancer (FMTC) is associated with an increased risk of developing MTC in early or middle adulthood, but it is not associated with the development of pheochromocytoma or parathyroid disease.

How is Pediatric Multiple Endocrine Neoplasia (MEN) diagnosed?

Genetic testing has proved to be a highly effective tool. For instance, testing of the RET genes can detect alterations in approximately 98% of individuals with MEN2A and MEN2B, and approximately 95% of families with familial medullary thyroid cancer.

Physicians can employ several methods for diagnosing MEN. Your child’s doctor may use a combination of these methods:

• Genetic testing
• Medical history and physical exam
• Family history
• Blood tests
• Thyroid ultrasound
• Possibly CT scan of the abdomen or head 
• Fine needle biopsy (removal of a small amount of tissue using a thin needle; the tissue is later examined under a microscope)

Testing

To determine, on a molecular level, if someone has Type 2 MEN2, a genetic test must be completed. This can be accomplished with a blood or saliva sample. DNA isolated from the sample enables RET gene evaluation. Alterations are identified and subjected to further examination.

Test results provide important genetic information for your family. As MEN is hereditary, results will indicate if other family members need to be tested to determine if they also carry the genetic mutation.

What are the causes of Pediatric Multiple Endocrine Neoplasia (MEN)?

MEN is caused by mutations at specific areas of your child’s genetic information. Every individual has a large amount of genetic information that is organized into the genes that instruct body cells to perform different functions.

• Type 1 MEN is caused by a defect in the MEN 1 gene, the gene responsible for producing a protein called menin. Menin acts as a tumor suppressor and normally keeps cells from growing and dividing too rapidly or in an uncontrolled way.
• Type 2 MEN is caused by a defect in the RET gene, the gene responsible for producing a protein called RET. The RET protein instructs cells to respond to their environment (for example, to divide or grow). Mutations in the RET gene “overactivate” the protein’s signaling function. In other words, the protein produced is always “switched on.” This can trigger cells to grow or divide too rapidly or in an uncontrolled way. In turn, this can lead to cancer development.

How is Pediatric Multiple Endocrine Neoplasia (MEN) treated?

Once a patient is diagnosed with MEN, they will need close follow up with a team of specialist. The treatment depends on the type of mutation and the age of the child at presentation.

Surgery

For those children with MEN2 specifically, they are at risk for developing thyroid cancer at a very early age so prophylactic thyroidectomy is recommended. Early detection and intervention to prevent and treat medullary thyroid cancer significantly improves disease-related mortality and morbidity.

Depending on the type of mutation (determined by genetic testing), surgery may be recommended in infancy.
Continued surveillance of these patients is critical due to their risk of recurrence and the risk of developing other tumors.